Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
US8481490B2 · kind B2 · utility
15Cited by
2References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 6, 2012 |
| Grant date | Jul 9, 2013 |
| Priority date | — |
| Expiry date | Aug 6, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.